MAPT and Alzheimer disease: This study also aimed to reduce the overexpression of Cdk5, thereby increasing the Mcl1 levels and potentially mitigating Aβ-amyloid and hyperphosphorylated tau formation in disease pathology in an AD cellular model by a designed peptide inhibitor targeting Cdk5.